225 related articles for article (PubMed ID: 21484384)
1. Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer.
Sgouros G; Hobbs RF; Atkins FB; Van Nostrand D; Ladenson PW; Wahl RL
Eur J Nucl Med Mol Imaging; 2011 May; 38 Suppl 1(Suppl 1):S41-7. PubMed ID: 21484384
[TBL] [Abstract][Full Text] [Related]
2. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software.
Sgouros G; Kolbert KS; Sheikh A; Pentlow KS; Mun EF; Barth A; Robbins RJ; Larson SM
J Nucl Med; 2004 Aug; 45(8):1366-72. PubMed ID: 15299063
[TBL] [Abstract][Full Text] [Related]
3. Monte Carlo-based 3-dimensional dosimetry of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using 124I PET.
Hobbs RF; Jentzen W; Bockisch A; Sgouros G
Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):79-91. PubMed ID: 23474639
[TBL] [Abstract][Full Text] [Related]
4. Acquisition settings for PET of 124I administered simultaneously with therapeutic amounts of 131I.
Lubberink M; van Schie A; de Jong HW; van Dongen GA; Teule GJ
J Nucl Med; 2006 Aug; 47(8):1375-81. PubMed ID: 16883019
[TBL] [Abstract][Full Text] [Related]
5. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer.
Jentzen W; Freudenberg L; Eising EG; Sonnenschein W; Knust J; Bockisch A
J Nucl Med; 2008 Jun; 49(6):1017-23. PubMed ID: 18483099
[TBL] [Abstract][Full Text] [Related]
6. 124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison.
Hobbs RF; Wahl RL; Lodge MA; Javadi MS; Cho SY; Chien DT; Ewertz ME; Esaias CE; Ladenson PW; Sgouros G
J Nucl Med; 2009 Nov; 50(11):1844-7. PubMed ID: 19837771
[TBL] [Abstract][Full Text] [Related]
7. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
[TBL] [Abstract][Full Text] [Related]
8. Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software.
Kolbert KS; Pentlow KS; Pearson JR; Sheikh A; Finn RD; Humm JL; Larson SM
J Nucl Med; 2007 Jan; 48(1):143-9. PubMed ID: 17204711
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET.
Eschmann SM; Reischl G; Bilger K; Kupferschläger J; Thelen MH; Dohmen BM; Besenfelder H; Bares R
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):760-7. PubMed ID: 12029549
[TBL] [Abstract][Full Text] [Related]
10. Dose-Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT.
Wierts R; Brans B; Havekes B; Kemerink GJ; Halders SG; Schaper NN; Backes WH; Mottaghy FM; Jentzen W
J Nucl Med; 2016 Jul; 57(7):1027-32. PubMed ID: 26917706
[TBL] [Abstract][Full Text] [Related]
11. Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma.
Salvatori M; Luster M
Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):821-8. PubMed ID: 20186542
[No Abstract] [Full Text] [Related]
12. The role of (124)I-PET in diagnosis and treatment of thyroid carcinoma.
Lubberink M; Abdul Fatah S; Brans B; Hoekstra OS; Teule GJ
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):30-6. PubMed ID: 17657202
[TBL] [Abstract][Full Text] [Related]
13. Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems.
Jentzen W; Weise R; Kupferschläger J; Freudenberg L; Brandau W; Bares R; Burchert W; Bockisch A
Eur J Nucl Med Mol Imaging; 2008 Mar; 35(3):611-23. PubMed ID: 17929014
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of 124I PET/CT imaging to predict absorbed doses in patients affected by metastatic thyroid cancer and treated with 131I.
Pettinato C; Monari F; Nanni C; Allegri V; Marcatili S; Civollani S; Cima S; Spezi E; Mazzarotto R; Fanti S
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):509-14. PubMed ID: 23358403
[TBL] [Abstract][Full Text] [Related]
15. 124-iodine positron emission tomography/computed tomography dosimetry in pediatric patients with differentiated thyroid cancer.
Freudenberg LS; Jentzen W; Marlowe RJ; Koska WW; Luster M; Bockisch A
Exp Clin Endocrinol Diabetes; 2007 Nov; 115(10):690-3. PubMed ID: 18058605
[TBL] [Abstract][Full Text] [Related]
16. Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in
Plyku D; Hobbs RF; Huang K; Atkins F; Garcia C; Sgouros G; Van Nostrand D
J Nucl Med; 2017 Jul; 58(7):1146-1154. PubMed ID: 28104741
[TBL] [Abstract][Full Text] [Related]
17. The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancer.
Weber M; Binse I; Nagarajah J; Bockisch A; Herrmann K; Jentzen W
Q J Nucl Med Mol Imaging; 2019 Sep; 63(3):235-252. PubMed ID: 31298014
[TBL] [Abstract][Full Text] [Related]
18. High Level of Agreement Between Pretherapeutic 124I PET and Intratherapeutic 131I Imaging in Detecting Iodine-Positive Thyroid Cancer Metastases.
Ruhlmann M; Jentzen W; Ruhlmann V; Pettinato C; Rossi G; Binse I; Bockisch A; Rosenbaum-Krumme S
J Nucl Med; 2016 Sep; 57(9):1339-42. PubMed ID: 27151981
[TBL] [Abstract][Full Text] [Related]
19. The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging.
Jentzen W; Balschuweit D; Schmitz J; Freudenberg L; Eising E; Hilbel T; Bockisch A; Stahl A
Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2298-306. PubMed ID: 20625723
[TBL] [Abstract][Full Text] [Related]
20. Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation.
Dewaraja YK; Wilderman SJ; Ljungberg M; Koral KF; Zasadny K; Kaminiski MS
J Nucl Med; 2005 May; 46(5):840-9. PubMed ID: 15872359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
